Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy

Cell Death and Differentiation

Volumn 22, Issue 11, 2015, Pages 1742-1753

  Morato L ^a,b,c   Ruiz, M ^a,b,c   Boada, J ^d   Calingasan, N Y ^e   Galino, J ^a,b,c   Guilera, C ^a,b,c   Jove M ^d   Naudi A ^d   Ferrer, I ^c,d   Pamplona, R ^d   Serrano, M ^g   Portero Otin M ^d   Beal, M F ^e,f   Fourcade, S ^a,b,c   Pujol, A ^a,b,c,h  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF LLEIDA   (Spain)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Centro Nacional de Investigaciones Oncológicas   (Spain)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID PRECURSOR PROTEIN; CELL NUCLEUS DNA; CYTOCHROME C; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; MALONALDEHYDE; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SYNAPTOPHYSIN; STILBENE DERIVATIVE;

ADRENOLEUKODYSTROPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISORDERS OF PEROXISOMAL FUNCTIONS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MITOCHONDRIAL RESPIRATION; MOUSE; NERVE FIBER DEGENERATION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; X LINKED ADRENOLEUKODYSTROPHY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; IN VITRO STUDY; LOCOMOTION; METABOLISM; MUTANT MOUSE STRAIN; WESTERN BLOTTING;

ADRENOLEUKODYSTROPHY; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HUMANS; IN VITRO TECHNIQUES; LOCOMOTION; MICE; MICE, MUTANT STRAINS; OXIDATION-REDUCTION; REAL-TIME POLYMERASE CHAIN REACTION; SIRTUIN 1; STILBENES;

EID: 84943198118     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.20     Document Type: Article

References (70)

1. Donmez G. The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol Sci 2012; 33: 494-501.
2. Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 2012; 23: 459-466.
3. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-295.
4. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
5. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1: 3.
6. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
7. Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M et al. PGC-1alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. FASEB J 2014; 28: 1745-1755.
8. Smith MR, Syed A, Lukacsovich T, Purcell J, Barbaro BA, Worthge SA et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014; 23: 2995-3007.
9. Court FA, Coleman MP. Mitochondria as a central sensor for axonal degenerative stimuli. Trends Neurosci 2012; 35: 364-372.
10. Ferrer I, Aubourg P, Pujol A. General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 2010; 20: 817-830.
11. Moser H, Smith KD, Watkins PA, Powers J, Moser AB. X-linked adrenoleukodystrophy In: Scriver C (ed) The Metabolic and Molecular Bases of Inherited disease8th ednvol. II. McGraw-Hill: New-York, 2001 pp 3257-3301.
12. Engelen M, Barbier M, Dijkstra IM, Schur R, de Bie RM, Verhamme C et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain 2014; 137: 693-706.
13. Wiesinger C, Kunze M, Regelsberger G, Forss-Petter S, Berger J. Impaired very long-chain acyl-CoA beta-oxidation in human X-linked adrenoleukodystrophy fibroblasts is a direct consequence of ABCD1 transporter dysfunction. J Biol Chem 2013; 288: 19269-19279.
14. Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20: 857-862.
15. Berger J, Pujol A, Aubourg P, Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20: 845-856.
16. Forss-Petter S,Werner H, Berger J, Lassmann H, Molzer B, Schwab MH et al. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res 1997; 50: 829-843.
17. Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA 1997; 94: 9366-9371.
18. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 2002; 11: 499-505.
19. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 2004; 13: 2997-3006.
20. Fourcade S, Lopez-Erauskin J, Galino J, Duval C, Naudi A, Jove M et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 2008; 17: 1762-1773.
21. Lopez-Erauskin J, Fourcade S, Galino J, Ruiz M, Schluter A, Naudi A et al. Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol 2011; 70: 84-92.
22. Galea E, Launay N, Portero-Otin M, Ruiz M, Pamplona R, Aubourg P et al. Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta 2012; 1822: 1475-1488.
23. Galino J, Ruiz M, Fourcade S, Schluter A, Lopez-Erauskin J, Guilera C et al. Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal 2011; 15: 2095-2107.
24. Morato L, Galino J, Ruiz M, Calingasan NY, Starkov AA, Dumont M et al. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain 2013; 136: 2432-2443.
25. Lopez-Erauskin J, Galino J, Ruiz M, Cuezva JM, Fabregat I, Cacabelos D et al. Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genet 2013; 22: 3296-3305.
26. Lopez-Erauskin J, Galino J, Bianchi P, Fourcade S, Andreu AL, Ferrer I et al. Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain 2012; 135: 3584-3598.
27. Fourcade S, Lopez-Erauskin J, Ruiz M, Ferrer I, Pujol A. Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. Biochimie 2014; 98: 143-149.
28. Powers JM, Pei Z, Heinzer AK, Deering R, Moser AB, Moser HW et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005; 64: 1067-1079.
29. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A et al. Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 2010; 19: 2005-2014.
30. Petrillo S, Piemonte F, Pastore A, Tozzi G, Aiello C, Pujol A et al. Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Mol Genet Metab 2013; 109: 366-370.
31. Vargas CR, Wajner M, Sirtori LR, Goulart L, Chiochetta M, Coelho D et al. Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 2004; 1688: 26-32.
32. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622.
33. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-690.
34. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74: 619-624.
35. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 2008; 105: 9793-9798.
36. Mastroeni R, Bensadoun JC, Charvin D, Aebischer P, Pujol A, Raoul C. Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol 2009; 66: 117-122.
37. de Vries RL, Przedborski S. Mitophagy and Parkinson's disease: be eaten to stay healthy. Mol Cell Neurosci 2013; 55: 37-43.
38. Launay N, Ruiz M, Fourcade S, Schluter A, Guilera C, Ferrer I et al. Oxidative stress regulates the ubiquitin-proteasome system and immunoproteasome functioning in a mouse model of X-adrenoleukodystrophy. Brain 2013; 136: 891-904.
39. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
40. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N Jr., Bennett DA et al. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 2009; 68: 48-58.
41. Zhang A, Wang H, Qin X, Pang S, Yan B. Genetic analysis of SIRT1 gene promoter in sporadic Parkinson's disease. Biochem Biophys Res Commun 2012; 422: 693-696.
42. Pallas M, Pizarro JG, Gutierrez-Cuesta J, Crespo-Biel N, Alvira D, Tajes M et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 2008; 154: 1388-1397.
43. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
44. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66: 352-361.
45. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
46. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
47. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010; 142: 320-332.
48. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-3179.
49. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280: 37377-37382.
50. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci 2012; 32: 124-132.
51. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2012; 18: 159-165.
52. Jiang M, Wang J, Fu J, Du L, Jeong H, West T et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2012; 18: 153-158.
53. Wang JT, Medress ZA, Barres BA. Axon degeneration: molecular mechanisms of a self-destruction pathway. J Cell Biol 2012; 196: 7-18.
54. Ferreirinha F, Quattrini A, Pirozzi M, Valsecchi V, Dina G, Broccoli V et al. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J Clin Invest 2004; 113: 231-242.
55. Fink JK. Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms. Acta Neuropathol 2013; 126: 307-328.
56. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-1013.
57. Suzuki K, Koike T. Resveratrol abolishes resistance to axonal degeneration in slowWallerian degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase. Biochem Biophys Res Commun 2007; 359: 665-671.
58. Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 2005; 170: 349-355.
59. Magnifico S, Saias L, Deleglise B, Duplus E, Kilinc D, Miquel MC et al. NAD+ acts on mitochondrial SirT3 to prevent axonal caspase activation and axonal degeneration. FASEB J 2013; 27: 4712-22.
60. Adalbert R, Nogradi A, Szabo A, Coleman MP. The slowWallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy. Eur J Neurosci 2006; 24: 2163-2168.
61. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100: 1512-1521.
62. Liu C, Shi Z, Fan L, Zhang C, Wang K, Wang B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res 2011; 1374: 100-109.
63. Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST et al. Resveratrol protects the brain of obese mice from oxidative damage. Oxid Med Cell Longev 2013; 2013: 419092.
64. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T et al. Evidence for a common mechanismof SIRT1 regulation by allosteric activators. Science 2013; 339: 1216-1219.
65. Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med 2014; 20: 179-187.
66. Magrane J, Sahawneh MA, Przedborski S, Estevez AG, Manfredi G. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci 2012; 32: 229-242.
67. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V et al. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 2005; 14: 3565-3577.
68. Fourcade S, Ruiz M, Camps C, Schluter A, Houten SM, Mooyer PA et al. A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 2009; 296: E211-E221.
69. Liu J, Sabeva NS, Bhatnagar S, Li XA, Pujol A, Graf GA. ABCD2 is abundant in adipose tissue and opposes the accumulation of dietary erucic acid (C22:1) in fat. J Lipid Res 2010; 51: 162-168.
70. Chabi B, Adhihetty PJ, O'Leary MF, Menzies KJ, Hood DA. Relationship between Sirt1 expression and mitochondrial proteins during conditions of chronic muscle use and disuse. J Appl Physiol (1985) 2009; 107: 1730-1735.